Enveric Biosciences Announces Broad Range of Patent Issuances
Enveric Biosciences (NASDAQ: ENVB) announces the expansion of patent protection for its EVM301 portfolio through five new US patents and three patent application allowances. The company now holds nine total US patents covering its drug candidate library. The patents cover various tryptamine derivative molecules, including carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivatives. The company's lead candidate, EB-003, targeting treatment-resistant depression and anxiety, is in preclinical development with planned IND filing in 2025. The compound shows potential for promoting neuroplasticity without inducing hallucinations.
Enveric Biosciences (NASDAQ: ENVB) annuncia l'espansione della protezione brevettuale per il suo portafoglio EVM301 attraverso cinque nuovi brevetti statunitensi e tre concessioni di domande di brevetto. L'azienda detiene ora un totale di nove brevetti statunitensi che coprono la sua libreria di candidati farmaceutici. I brevetti riguardano vari tipi di molecole derivate dal triptamino, inclusi derivati carboxilati, amminati, prenilati, glicosilati, nitrilati e alogenati. Il candidato principale dell'azienda, EB-003, volto al trattamento della depressione e dell'ansia resistenti ai trattamenti, è in fase di sviluppo preclinico con una richiesta di IND pianificata per il 2025. Il composto mostra potenziale per promuovere la neuroplasticità senza indurre allucinazioni.
Enveric Biosciences (NASDAQ: ENVB) anuncia la expansión de la protección de patentes para su cartera EVM301 a través de cinco nuevas patentes en EE. UU. y tres aprobaciones de solicitudes de patentes. La compañía ahora posee un total de nueve patentes estadounidenses que cubren su biblioteca de candidatos a fármacos. Las patentes cubren varias moléculas derivadas de tryptamina, incluyendo derivados carboxilados, aminados, prenilados, glicosilados, nitrilados y halogenados. El candidato principal de la compañía, EB-003, que se dirige al tratamiento de la depresión y la ansiedad resistentes a tratamientos, está en desarrollo preclínico con una presentación de IND planificada para 2025. El compuesto muestra potencial para promover la neuroplasticidad sin inducir alucinaciones.
엔베릭 생명과학 (NASDAQ: ENVB)은 EVM301 포트폴리오의 특허 보호를 다섯 개의 신규 미국 특허와 세 개의 특허 출원 허가를 통해 확장한다고 발표했습니다. 이 회사는 현재 의약 후보 라이브러리를 다루는 총 아홉 개의 미국 특허를 보유하고 있습니다. 이 특허들은 카르복실화, 아민화, 프레닐화, 글리코실화, 니트릴화 및 할로겐화된 유도체를 포함한 다양한 트립타민 유도체 분자를 다룹니다. 회사의 주요 후보인 EB-003은 치료에 저항성 있는 우울증과 불안을 대상으로 하며, 2025년 IND 제출을 계획하고 있는 전임상 개발 단계에 있습니다. 이 화합물은 환각을 유도하지 않으면서 신경가소성을 촉진할 가능성을 보여줍니다.
Enveric Biosciences (NASDAQ: ENVB) annonce l'expansion de la protection par brevet pour son portefeuille EVM301 grâce à cinq nouveaux brevets américains et trois autorisations de demande de brevet. L'entreprise détient désormais un total de neuf brevets américains couvrant sa bibliothèque de candidats médicamenteux. Les brevets portent sur diverses molécules dérivées du tryptamine, y compris des dérivés carboxylés, aminés, prénylés, glycosylés, nitrilés et halogénés. Le principal candidat de l'entreprise, EB-003, ciblant le traitement de la dépression et de l'anxiété résistantes aux traitements, est en développement préclinique avec un dépôt d'IND prévu pour 2025. Le composé montre un potentiel pour promouvoir la neuroplasticité sans induire d'hallucinations.
Enveric Biosciences (NASDAQ: ENVB) gibt die Erweiterung des Patentschutzes für sein EVM301-Portfolio durch fünf neue US-Patente und drei Genehmigungen von Patentanmeldungen bekannt. Das Unternehmen besitzt nun insgesamt neun US-Patente, die seine Arzneimittelkandidatenbibliothek abdecken. Die Patente decken verschiedene Tryptamin-Derivate ab, einschließlich carboxylierter, aminierter, prenylierter, glykosylierter, nitrilierter und halogener Derivate. Der Hauptkandidat des Unternehmens, EB-003, der auf die Behandlung von therapieresistenter Depression und Angst abzielt, befindet sich in der präklinischen Entwicklung mit einer geplanten IND-Anmeldung im Jahr 2025. Die Verbindung zeigt Potenzial zur Förderung der Neuroplastizität, ohne Halluzinationen auszulösen.
- Secured five new US patents and three patent allowances, strengthening IP protection
- Portfolio includes molecules with potential applications in antiepileptic and anti-obesity treatments
- Lead candidate EB-003 shows favorable safety profile without hallucination side effects
- Expanded protection covers over 1,000 tryptamine derivative molecules
- Lead candidate EB-003 still in preclinical phase, with IND filing not expected until 2025
Insights
The issuance of five new patents and allowance of three additional patent applications significantly strengthens Enveric's intellectual property portfolio around their EVM301 platform. The expanded patent protection now covers diverse tryptamine derivatives including carboxylated, aminated, prenylated, glycosylated, nitrilated and halogenated variants. This comprehensive IP coverage is particularly valuable for a small-cap biotech, as it creates multiple potential commercialization pathways and increases licensing opportunities.
The patents' scope specifically protecting compounds with enhanced 5-HT2C receptor selectivity is strategically important, as it opens additional therapeutic opportunities in lucrative markets like epilepsy and obesity. For a company with a
The company's focus on developing compounds with selective 5-HT2C receptor targeting while minimizing activity at other serotonergic receptors represents a sophisticated approach to neuropsychiatric drug development. Their lead candidate EB-003's potential to promote neuroplasticity without hallucinations addresses a critical safety concern in psychedelic medicine. This differentiation could provide significant advantages over current psychedelic compounds in development.
The breadth of their Psybrary™ with over 1,000 tryptamine derivatives provides multiple shots on goal for developing therapeutics across various CNS indications. The planned IND filing in 2025 for EB-003 targeting treatment-resistant depression and anxiety provides a clear development timeline and potential value inflection point.
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric’s drug candidate library
The
“The increasing depth and breadth of the EVM301 portfolio of molecules with strong intellectual property backing expands the value-capture opportunities available to Enveric,” said Dr. Joseph Tucker, CEO of Enveric. “The EVM301 portfolio extends across a broad range of tryptamine derivative molecules including, but not limited to, carboxylated, aminated, prenylated, glycosylated, nitrilated, and halogenated derivative molecules, and combinations of two or more of these functional motifs, in the form of multi-substituent tryptamine derivatives.”
Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued patent claims, with potential as antiepileptic and anti-obesity drug candidates, which have demonstrated enhanced binding preference for the 5-HT2C receptor relative to other serotonergic, dopaminergic, and adrenergic receptor targets,” reported Dr. Tucker.
The lead candidate derived from the EVM301 Series of compounds, EB-003, which targets major undertreated mental health indications including treatment-resistant depression and anxiety, is currently in preclinical development to support filing an Investigational New Drug (IND) application in 2025. The favorable safety profile of EB-003 is supported by receptor engagement data with key serotonergic targets that suggest the ability to promote clinically important neuroplasticity without inducing hallucinations, a significant safety concern limiting the potential to reach patients.
About Enveric Biosciences
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of new chemical entities for specific mental health indications. Enveric’s lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, a next generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment for psychiatric disorders. Enveric is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposes,” “budgets,” “schedules,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: negotiate and finalize definitive agreements based on any of its out-licensing term sheets and perform pursuant to the terms thereof; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104428250/en/
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Source: Enveric Biosciences
FAQ
What new patents did Enveric Biosciences (ENVB) receive in 2024?
When will Enveric Biosciences (ENVB) file IND for EB-003?
What conditions does Enveric Biosciences (ENVB) EB-003 target?
